ReviewHeart failure reviews2015
Bone marrow-derived mesenchymal stem cells for the treatment of heart failure.
Review in Heart failure reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Intracoronary Mesenchymal Stem Cell Administration in ST-Segment Elevation Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.Clinical and translational science · 2026Pooled it
- Bone marrow mesenchymal stem cells transfer in patients with ST-segment elevation myocardial infarction: single-blind, multicenter, randomized controlled trial.Stem cell research & therapy · 2021Trial
- Mitochondrial Transfer: From Bench to Bedside.Circulation research · 2026Review
- Stem Cell Therapy and Models for Autism Spectrum Disorder: Insights and Research.Current neuropharmacology · 2026Review
- Stem Cell Therapies in Canine Cardiology: Comparative Efficacy, Emerging Trends, and Clinical Integration.Biomolecules · 2025Review
- Article
- Bone marrow mesenchymal stem cells-derived exosomal lncRNA GAS5 mitigates heart failure by inhibiting UL3/Hippo pathway-mediated ferroptosis.European journal of medical research · 2024Article
- Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments.Biomedicines · 2023Review
- STEMIN and YAP5SA synthetic modified mRNAs regenerate and repair infarcted mouse hearts.The journal of cardiovascular aging · 2022Article
- Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier.Global heart · 2022Review
- Mesenchymal Stem Cell-Derived Extracellular Vesicles Therapy for Pulmonary Hypertension: A Comprehensive Review of Preclinical Studies.Journal of interventional cardiology · 2022Review
- Epicardial placement of human MSC-loaded fibrin sealant films for heart failure: Preclinical efficacy and mechanistic data.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Engineered cell-degradable poly(2-alkyl-2-oxazoline) hydrogel for epicardial placement of mesenchymal stem cells for myocardial repair.Biomaterials · 2021Article
- Extracellular Vesicles Derived From Human Umbilical Cord Mesenchymal Stem Cells Protect Against DOX-Induced Heart Failure Through the miR-100-5p/NOX4 Pathway.Frontiers in bioengineering and biotechnology · 2021Article
- 1,25(OH)Drug design, development and therapy · 2020Article
- On-site fabrication of Bi-layered adhesive mesenchymal stromal cell-dressings for the treatment of heart failure.Biomaterials · 2019Article
- Therapeutic potential of menstrual blood-derived endometrial stem cells in cardiac diseases.Cellular and molecular life sciences : CMLS · 2019Review
- Cell-Based Therapies for Cardiac Regeneration: A Comprehensive Review of Past and Ongoing Strategies.International journal of molecular sciences · 2018Review
- Regenerative Therapy for Cardiomyopathies.Journal of cardiovascular translational research · 2018Review
- Fibrin Glue-aided, Instant Epicardial Placement Enhances the Efficacy of Mesenchymal Stromal Cell-Based Therapy for Heart Failure.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Heart failure remains a major cause of death and disability, requiring rapid development of new therapies. Bone marrow-derived mesenchymal stem cell (MSC)-based therapy is an emerging approach for the treatment of both acute and chronic heart failure. Following successful experimental studies in a range of models, more than 40 clinical trials of MSC-based therapy for heart failure have now been registered, and the results of completed clinical trials so far have shown feasibility and safety of this approach with therapeutic potential suggested (though preliminarily). However, there appear to be several critical issues to be solved before this treatment could become a widespread standard therapy for heart failure. In this review, we comprehensively and systemically summarize a total of 73 preclinical studies and 11 clinical trial reports published to date. By analyzing the data in these reports, (1) improvement in the cell delivery method to the heart in order to enhance donor cell engraftment, (2) elucidation of mechanisms underpinning the therapeutic effects of the treatment differentiation and/or treatment secretion, and (3) validation of the utility of allogeneic MSCs which could enhance the efficacy and expand the application/indication of this therapeutic approach are highlighted as future perspectives. These important respects are further discussed in this review article with referencing latest scientific and clinical information.
Indexed as
Identifiers
24862087What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.